Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Gynecologic Cancer 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 46lenvatinib 44apatinib 23sintilimab 22Fluorouracil 21camrelizumab 20Oxaliplatin 17Radiofrequency Ablation 16Radiosurgery 15Hepatectomy 15tislelizumab 14Leucovorin 14Radiotherapy 12Doxorubicin 12toripalimab 11Folfox protocol 10Bevacizumab 10Immune Checkpoint Inhibitors 9Epirubicin 9regorafenib 8Ethiodized Oil 8durvalumab 7donafenib 7anlotinib 7Neoadjuvant Therapy 7pembrolizumab 6entecavir 6Surgical Procedures, Operative 6Nivolumab 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Hepatocellular × Enhanced Recovery After Surgery × Clear all
NCT02644603 2017-06-27

Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer

Shanghai Zhongshan Hospital

Phase NA Unknown
214 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡